Skip to main content
SpringerLink
Log in

Prophylactic intervention in radiation-leukemia-virus-induced murine lymphoma by the biological response modifier polysaccharide K

  • Original Article
  • RadLV, Lymphoma, PSK, Superantigen, Prevention
  • Published:
Cancer Immunology, Immunotherapy Aims and scope Submit manuscript

Abstract

Polysaccharide K (PSK) is a biological response modifier used for adjuvant immunotherapy of malignant diseases. We studied the potential applicability of PSK for preventing tumor progression using an experimental model of murine lymphoma. Mice inoculated with the radiation leukemia virus (RadLV) develop thymic lymphomas after a latency of 3–6 months. However, 2 weeks after virus inoculation, prelymphoma cells can already be detected in the thymus. We found that PSK treatment induced hyperresponsiveness to concanavalin A and heightened production of interleukin-2 (IL-2) and IL-4 in spleen cells of both control and prelymphoma mice. The response was transient and was accompanied with a dominant usage of T cells expressing Vβ8, but other T cell subsets were also stimulated by PSK. T lymphoma cells expressing Vβ8.2 underwent apoptosis when incubated with PSK. Treatment of RadLV-inoculated mice with PSK delayed the onset of overt lymphoma (and mortality) but could not protect the mice from the disease. Combined treatment with PSK and a RadLV-specific immunotoxin prevented synergistically the progression of the prelymphoma cells to frank lymphoma. The results suggest that PSK contains a superantigen-like component that selectively activates Vβ8+ T cells. Its administration prelymphoma mice interfered with the process of lymphoma progression.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Tsukagoshi S, Hashimoto Y, Fujii G, Kobayashi H, Nomoto K, Orita K (1984) Krestin (PSK). Cancer Treat Rev 11: 131

    Google Scholar 

  2. Ebihara K, Minamishima Y (1984) Protective effect of biological response modifiers on murine cytomegalovirus infection. J Virol 51: 117

    Google Scholar 

  3. Enrke MJ, Reino JM, Eppolito C, Mihich E (1983) The effect of PSK, a protein bound polysaccharide on immune responses against allogeneic antigens. Int J Immunopharmacol 5: 35

    Google Scholar 

  4. Hosokawa M, Mizukoshi T, Sugawara M, Kobayashi H (1985) Therapeutic effects of PSK and busulfan on the recurrent and metastatic diseases after the surgical removal of 3-methylcholanthrene-induced autochtonous tumors in C57BL/6 mice. Gann 76: 61

    Google Scholar 

  5. Kondo M, Kato H, Yokoe N, Matsumura N, Hotta T, Masasuke M (1978) Activation of the complement by immunostimulants, BCG, OK-432 (Picibani), and PS-K (Krestin) in vitro. Gann 69: 699

    Google Scholar 

  6. Mizushima Y, Yuhki N, Hosokawa M, Kobayashi H (1982) Diminution of cyclophosphamide-induced suppression of antitumor immunity by an immunomodulator PSK and combined therapeutic effects of PSK and cyclophosphamide on transplanted tumor in rats. Cancer Res 42: 5176

    Google Scholar 

  7. Nomoto K, Yoshikumi C, Matsunaga K, Fujii T, Takeya K (1975) Restoration of antibody-forming capacities by PS-K in tumorbearing mice. Gann 66: 365

    Google Scholar 

  8. Tsurku S, Nomoto K (1983) Effects of PSK on specific tumor immunity to syngeneic tumor cells. J Clin Lab Immunol 4: 215

    Google Scholar 

  9. Torisu M, Hayashi Y, Ishimitsu T, Fujimura T, Iwasaki K, Katano M, Yamamoto H, Kimura Y, Takesue M, Motoharu K, Nomoto K (1990) Significant prolongation of disease-free period gained by oral polysaccharide K (PSK) administration after curative surgical operation of colorectal cancer. Cancer Immunol Immunother 31: 261

    Google Scholar 

  10. Nakazato H, Koike A, Saji S, Ogawa N, Sakamoto J (1994) Efficacy of immunochemotherapy as adjuvant treatment after curative resection of gastric cancer. Lancet 343: 1122

    Google Scholar 

  11. Mitomi T (1992) Randomized, controlled study on adjuvant immunochemotherapy with PSK in curatively resected colorectal cancer. Dis Colon Rectum 35: 123

    Google Scholar 

  12. Fujii T, Saito K, Oguchi Y, Matsunaga K, Kobayashi Y, Yoshikumi C, Taguchi T (1988) Effects of the protein-bound polysacharide preparation, PSK on spontaneous breast cancer in mice. J Int Med Res 16: 286

    Google Scholar 

  13. Yamane T, Fujita Y, Sagara Y, Okuzumi J, Kuwata K, Tanaka M, Takahashi T (1989) The effect of a protein-bound polysaccharide preparation, PS-K, on carcinogenesis in the glandular stomach of rats induced byN-methyl-N'-nitro-N-nitrosoguanidine. J Kyoto Prefect Univ Med 98: 307

    Google Scholar 

  14. Nakajima T, Ichikawa S, Uchida S, Komada T (1990) Effects of a protein-bound polysaccharide from a basidiomycetes against hepatocarcinogenesis induced by ′3-methyl-4-dimethylaminoazobenzene in rats. Clin Ther 12: 385

    Google Scholar 

  15. Henderson BE, Ross RK, Pike MC (1991) Towards the primary prevention of cancer. Science 254: 1131

    Google Scholar 

  16. Baum M, Ziv Y, Colletta AA (1991) Can we prevent breast cancer? Br J Cancer 66: 205

    Google Scholar 

  17. Klein G, Klein E (1985) Evolution of tumors and the impact of molecular oncology. Nature 315: 190

    Google Scholar 

  18. Weinberg RA (1989) Oncogenes, antioncogenes, and the molecular bases of multistep carcinogenesis. Cancer Res 49: 3713

    Google Scholar 

  19. Vogelstein B, Kinzler KW (1993) The multistep nature of cancer. Trends Genet 9: 138

    Google Scholar 

  20. Wakefield LA, Sporn MB (1990) Suppression of carcinogenesis: a role for TGF-β and related molecules in prevention of cancer. In: Klein G (ed) Tumor suppressor genes. Dekker, New York, p 217

    Google Scholar 

  21. Haran-Ghera N (1978) Spontaneous and induced preleukemia cells in C57BL/6 mice. J Natl Cancer Inst 60: 707

    Google Scholar 

  22. Haran-Ghera N, Peled A (1979) Induction of leukemia in mice by irradiation and radiation leukemia virus variants. Adv Cancer Res 30: 45

    Google Scholar 

  23. Ben-David Y, Kotler M, Yefenof E (1987) Leukemogenic, immunogenic and genetic properties of a thymotropic radiation leukemia virus. Int J Cancer 39: 492

    Google Scholar 

  24. Ben-David Y, Yefenof E, Kotler M (1987) Clonal analysis of radiation leukemia virus (RadLV) induced leukemic and preleukemic cells. Cancer Res 47: 6590

    Google Scholar 

  25. Yefenof E, Epsztein S, Kotler M (1991) Quantitation, in vitro propagation and characterization of preleukemic cells induced by radiation leukemia virus. Cancer Res 51: 2179

    Google Scholar 

  26. Yefenof E, Ela C, Kotler M, Vitetta ES (1992) Induction of IL-4 secretion by the radiation leukemia virus (RadLV): role in autocrine growth stimulation of RadLV infected pre-leukemic cells. Int J Cancer 50: 481

    Google Scholar 

  27. Yefenof E, Abboud G, Epsztein S, Vitetta ES (1992) Treatment of premalignancy: prevention of lymphoma in radiation leukemia virus inoculated mice by cyclosporin A and immunotoxin. Proc Natl Acad Sci USA 89: 728

    Google Scholar 

  28. Haas M (1974) Continuous production of radiation leukemia virus in C57BL thymona tissue culture lines: purification of the leukemogenic virus. Cell 1: 79

    Google Scholar 

  29. Haran-Ghera N, Ben-Yaakov M, Peled A (1977) Immunologic characteristics in relation to high and low leukemogenic activity of radiation leukemia virus variants. J Immunol 118: 600

    Google Scholar 

  30. Yefenof E, Meidav A, Kedar E (1980) In vitro generation of cytotoxic lymphocytes against radiation and radiation leukemia virus (RadLV) induced tumors: III. Suppression of anti-tumor immunity in vitro by lymphocytes of mice undergoing RadLV induced leukemogenesis. J Exp Med 152: 1473

    Google Scholar 

  31. Fulton RJ, Uhr JW, Vitetta ES (1988) In vitro therapy of the BCL1 tumor: Effect of immunotoxin valency and deglycosylation of the ricin A chain. Cancer Res 48: 2626

    Google Scholar 

  32. Pullen AM, Marrack P, Kappler JW (1988) The T cell repertoire is heavily influenced by tolerance to polymorphic self antigens. Nature 335: 796

    Google Scholar 

  33. Tomonari K, Lovering E, Spencer S (1990) Correlation between the Vβ4+CD8+ T cell population and the H-2d haplotype. Immunogenetics 31: 333

    Google Scholar 

  34. MacDonald HR, Schneider R, Less RK, Howe RC, Acha-Orbea H, Festenstein H, Zinkernagel RM, Hengartner H (1988) T-cell receptor Vβ use predicts reactivity and tolerance to Mlsa-encoded antigens. Nature 332: 40

    Google Scholar 

  35. Staerz U, Rammensee H, Benedetto J, Bevan M (1985) Characterization of a murine monoclonal antibody specific for an allotypic determinant on T cell antigen receptor. J Immunol 134: 3994

    Google Scholar 

  36. Haskins K, Hannum C, White J, Roehm N, Kubo R, Kappler J, Marrack P (1984) The antigen specific, major histocompatibility complex-restricted receptor on T cells. VI. An antibody to a receptor allotype. J Exp Med 160: 452

    Google Scholar 

  37. Kappler JW, Staerz U, White J, Marrack PC (1988) Self-tolerance eliminates T cells specific for M1s-modified products of the major histocompatibility complex. Nature 332: 35

    Google Scholar 

  38. Tomonari K, Lovering E (1988) T cell receptor specific monoclonal antibodies against a Vβ11 positive mouse T cell clones. Immunogenetics 28: 445

    Google Scholar 

  39. Kappler JW, Wade T, White J, Kushner E, Blackman M, Bill J, Roehm N, Marrack P (1987) A T cell receptor Vβ segment that imparts reactivity to a class II major histocompatibility complex product. Cell 49: 263

    Google Scholar 

  40. Wyllie AH (1980) Glucocorticoid-induced thymocyte apoptosis is associated with endogenous endonuclease activation. Nature 284: 555

    Google Scholar 

  41. Reference deleted

  42. Fleischer B (1992) Superantigens. Curr Opin Immunol 4: 392

    Google Scholar 

  43. Yefenof E, Einat E, Klein E (1991) Potentiation of T cell immunity against radiation-leukemia-virus-induced lymphoma by polysaccharide K. Cancer Immunol Immunother 34: 133

    Google Scholar 

  44. Boccoli G, Masciulli R, Ruggeri EM, Carlini P, Giannella G, Mongtesoro E, Mastroberardino G, Isacchi G, Testa U, Calabresi F, Peschle C (1990) Adoptive immunotherapy of human cancer: the cytokine cascade and monocyte activation following high-dose Interleukin 2 Bolus treatment. Cancer Res 50: 5795

    Google Scholar 

  45. Dupere S, Obiri N, Lackey A, Emma D, Yannelli J, Orr D, Birch R, O'Conner TE (1990) Patterns of cytokines released by peripheral blood leukocytes of normal donors and cancer patients during interleukin-2 activation in vitro. J Biol Responses Mod 9: 140

    Google Scholar 

  46. Economou JS, Hoban M, Lee JD, Essner R, Swisher S, McBride W, Hoon DB, Morton DL (1991) Production of tumor necrosis factor α and interferon γ in interleukin-2-treated melanoma patients: correlation with clinical toxicity. Cancer Immunol Immunother 34: 49

    Google Scholar 

  47. Vetto JT, Papa MZ, Lotze MT, Chang AE, Rosenberg SA (1987) Reduction of toxicity of interleukin-2 and lymphokine-activated killer cells in humans by the administration of corticosteroids. J Clin Oncol 5: 496

    Google Scholar 

  48. Margolin KA, Rayner AA, Hawkins MJ, Atkins MB, Dutcher JP, Fisher RI, Weiss GR, Doroshow JH, Jaffe HS, Roper M, Parkinson DR, Wiernik PH, Creekmore SP, Boldt DH (1989) Interleukin-2 and lymphokine-activated killer cell therapy of solid tumors: analysis of toxicity and management guidelines. J Clin Oncol 7: 486

    Google Scholar 

  49. Bukowski RM, Murthy S, Sergi J, Budd GT, McKeever S, Medendorp SV, Tubbs R, Gibson V, Finke J (1990) Phase I trial of continuous infusion recombinant interleukin-2 and intermittent recombinant interferon-α2a: Clinical effects. J Biol Response Mod 9: 538

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. The Lautenberg Center for General and Tumor Immunology, Hebrew University-Hadassah Medical School, POB 12272, 91120, Jerusalem, Israel

    E. Yefenof, I. Gafanovitch, E. Oron & M. Bar

  2. Microbiology and Tumorbiology Center, Karolinska Institute, Stockholm, Sweden

    E. Klein

Authors
  1. E. Yefenof
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. I. Gafanovitch
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. E. Oron
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M. Bar
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. E. Klein
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Yefenof, E., Gafanovitch, I., Oron, E. et al. Prophylactic intervention in radiation-leukemia-virus-induced murine lymphoma by the biological response modifier polysaccharide K. Cancer Immunol Immunother 41, 389–396 (1995). https://doi.org/10.1007/BF01526559

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01526559

Key words

Search

Navigation